Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 April 2024
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Camlipixant for treating refractory or unexplained chronic cough [TSID12072]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC